Type 2 Diabetes Medications: A Guide to Drugs & Treatment Options

For decades, metformin was the standard first-line medication prescribed to most individuals newly diagnosed with type 2 diabetes. However, a shift is occurring in treatment approaches, with many physicians, particularly endocrinologists, increasingly favoring alternative medications. This change reflects a growing emphasis on protecting vital organs – the kidneys and heart – in diabetes management.

A Changing Landscape in Diabetes Medication

While primary care physicians may still adhere to older guidelines recommending metformin as the initial treatment, specialists are leaning towards GLP-1 receptor agonists and SGLT2 inhibitors as superior options. Michael Uzmann, MD, an endocrinologist at A1Endocrinology in Las Vegas, notes that many endocrinologists have been utilizing these newer therapies for nearly a decade. This evolving perspective underscores a more proactive approach to mitigating the long-term complications of type 2 diabetes.

Did You Know? Metformin remains the only biguanide medication available in the United States and is recommended by the American Diabetes Association for some high-risk adults with prediabetes.

Menachem Jacobs, MD, medical cofounder at Outlive Biology and a resident physician at Yale New Haven Hospital, explains his recent strategic shift. His priority is now focused on safeguarding the kidneys and heart. For patients with existing renal disease or heart failure, SGLT2 inhibitors or GLP-1 agonists are his preferred choices, as he believes these medications can be “organ saving.”

Understanding the Medication Classes

Several classes of medications are available to manage type 2 diabetes, each working through different mechanisms. Here’s a breakdown of the main categories:

Biguanides

Metformin is the sole drug in this class currently available in the U.S. It functions by reducing glucose production in the liver and improving the body’s response to insulin. Potential side effects include nausea, diarrhea, and vomiting, but these can often be mitigated by taking the medication with food. This proves not recommended for individuals with decreased kidney function, heart failure, or alcohol dependence, and long-term use may lead to vitamin B12 deficiency.

GLP-1 Receptor Agonists

These medications mimic a natural hormone that stimulates insulin release when you eat. They also slow digestion and suppress appetite, potentially leading to significant weight loss. Most are administered via injection, although semaglutide (Rybelsus) is available in pill form. Medications in this class include dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Victoza), lixisenatide (Adlyxin), and semaglutide (Ozempic, Rybelsus). Possible side effects include nausea, vomiting, diarrhea, and, rarely, pancreatitis.

Dual and Triple Agonists

Representing a newer generation of diabetes medications, dual and triple agonists target multiple hormone receptors to enhance blood sugar control and promote weight loss. Dual agonists act on both GLP-1 and GIP receptors, while triple agonists, currently in clinical trials, target GLP-1, GIP, and glucagon receptors. Tirzepatide is a medication in this class, and potential side effects include nausea, vomiting, diarrhea, and constipation.

Expert Insight: The shift away from metformin as a first-line treatment reflects a growing understanding of the interconnectedness of diabetes with cardiovascular and renal health. Prioritizing these organ systems early in treatment could significantly improve long-term patient outcomes.

SGLT2 Inhibitors

SGLT2 inhibitors prevent the kidneys from reabsorbing sugar, allowing it to be excreted through urine. These drugs are particularly recommended for individuals with heart failure or chronic kidney disease. Medications in this class include bexagliflozin (Brenzavvy), canagliflozin (Invokana), dapagliflozin (Farxiga), empagliflozin (Jardiance), and ertugliflozin (Steglatro). Possible side effects include increased urinary frequency, dizziness, yeast infections, urinary tract infections, and dehydration. Rarely, these medications can cause low blood pressure or diabetic ketoacidosis.

DPP-4 Inhibitors

DPP-4 inhibitors enhance insulin release by blocking the enzyme that breaks down incretin hormones. Medications in this class include alogliptin (Nesina), linagliptin (Tradjenta), saxagliptin, and sitagliptin (Januvia). Potential side effects include headaches, nausea, and joint pain, and may increase the risk of pancreatitis or heart failure in individuals with pre-existing heart conditions.

Sulfonylureas

These older medications stimulate the pancreas to release more insulin. While effective and inexpensive, they carry a higher risk of hypoglycemia (low blood sugar) and weight gain. Medications in this class include glimepiride, glipizide, and glyburide (DiaBeta). Side effects can include nausea, skin reactions, and diarrhea, and they are not recommended for those with kidney or liver disease.

Meglitinides

Like sulfonylureas, meglitinides trigger insulin release from the pancreas, but they act more rapidly. Possible side effects include hypoglycemia and weight gain. Medications in this class are repaglinide and nateglinide.

Thiazolidinediones

Thiazolidinediones (TZDs) improve insulin sensitivity. However, they are prescribed less frequently due to potential risks of heart failure and bone fractures. Medications in this class include pioglitazone (Actos) and rosiglitazone.

D2 Argonist

Bromocriptine (Cycloset, Parlodel) is an oral medication that can help lower blood sugar. Side effects may include blurred vision, headache, and nausea, which often subside as the body adjusts.

Insulin

If other medications are insufficient to manage blood sugar levels, insulin therapy may be necessary. Insulin replaces the hormone the body isn’t producing adequately. Kathleen Dungan, MD, an endocrinologist at the Ohio State University Wexner Medical centre, notes that patients typically begin with a single daily injection of long-acting insulin.

Frequently Asked Questions

What is metformin and why was it previously the first choice for type 2 diabetes?

Metformin is a biguanide medication that lowers glucose production in the liver and improves the body’s response to insulin. For a long time, it was the first medication prescribed because of its effectiveness and established safety profile.

What are GLP-1 receptor agonists and SGLT2 inhibitors?

GLP-1 receptor agonists mimic a natural hormone to stimulate insulin release and reduce appetite, while SGLT2 inhibitors prevent the kidneys from reabsorbing sugar, allowing it to be excreted in urine. Both are increasingly favored for their benefits in protecting the heart and kidneys.

What are the potential side effects of these medications?

Side effects vary depending on the medication class. Metformin can cause nausea and diarrhea, GLP-1 agonists can cause gastrointestinal issues, SGLT2 inhibitors can lead to infections, and sulfonylureas carry a risk of hypoglycemia. Each medication has a specific profile of potential side effects.

As research continues and our understanding of type 2 diabetes evolves, it will be interesting to see how treatment strategies adapt to prioritize not only blood sugar control, but also the long-term health of the heart and kidneys.